Clinical Trials Browser

decitabine and cedazuridine drug combination × Other solid neoplasm × 90 days × Clear all

NCT05960773 2026-03-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Phase 2 Suspended

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma